Today, at the highly anticipated "ChinaVenture 20th Annual Investment Summit · Annual Conference," the prestigious ChinaVenture Awards list was officially unveiled. Leveraging its deep expertise in the healthcare industry, EFUNG Capital swept multiple significant institutional and individual awards.
EFUNG Capital was honored with: ChinaVenture 2025 Top 50 Best RMB-denominated Venture Capital Firms, ChinaVenture 2025 Top 20 Medical Device Investment Institutions in the Healthcare Sector, and ChinaVenture 2025 Top 100 Best Venture Capital Firms.
At the same time, Mr. Zhu Pai, CEO of EFUNG Capital, stood out among the new generation of investors and was awarded: ChinaVenture 2025 NOVA Rising Star Investor Top 50.
Portfolio companies within the EFUNG Capital ecosystem also delivered outstanding performances. Core Medical and Nurotron successfully made the list: ChinaVenture 2025 Top 10 Medical Device Investment Cases in the Healthcare Sector.
The ChinaVenture Awards are an authoritative ranking published for 20 consecutive years by the independent third-party institution, ChinaVenture Information. Based on ChinaVenture's massive data system and rigorous research process, combined with feedback from over a thousand active investment institutions, the awards select outstanding firms through professional evaluation criteria and data verification.
As a "bellwether" of the domestic equity investment industry, this ranking not only faithfully records the annual evolution of the sector but also serves as a crucial reference for major institutional limited partners (LPs) in making capital allocation decisions. The 2025 awards deeply reflect the new trend of investment institutions transitioning from financial investment to industrial empowerment, against the backdrop of a renminbi-fund-dominated market and an unprecedented concentration on hard-tech investing.
EFUNG Capital Honored with:
ChinaVenture 2025 Top 50 Best RMB-denominated Venture Capital Firms
ChinaVenture 2025 Top 20 Medical Device Investment Institutions in the Healthcare Sector
ChinaVenture 2025 Top 100 Best Venture Capital Firms
Zhu Pai, CEO of EFUNG Capital, Honored with:
EFUNG Capital Portfolio Companies Core Medical and Nurotron Honored with:
Looking ahead, EFUNG Capital will continue to deepen its full-industry-chain layout in biomedicine and high-end medical devices, further empower its portfolio companies, support the innovation and upgrading of China's healthcare industry, and embrace the spring of long-term value together with its investors and partners.